Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

被引：0
|
作者：
Prithviraj, Prashanth
McArthur, Grant A.
Atkinson, Victoria
Parente, Phillip
Andrews, Miles Cameron
Parakh, Sagun
Cebon, Jonathan S.
Klein, Oliver
机构：
[1] Austin Hlth, Med Oncol Unit, Heidelberg, Vic, Australia
[2] Peter MacCallum Canc Ctr, East Melbourne, Australia
[3] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia
[4] Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
[5] Austin Hosp, Heidelberg, Vic, Australia
[6] Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9059
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [42] Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
    Azuma, Takeshi
    Takeuchi, Takumi
    Matayoshi, Yukihide
    Namiki, Shin
    Obara, Tetsuya
    Imamura, Kazuhiro
    Takamori, Mikio
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [43] Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody
    Takeshi Azuma
    Takumi Takeuchi
    Yukihide Matayoshi
    Shin Namiki
    Tetsuya Obara
    Kazuhiro Imamura
    Mikio Takamori
    Scientific Reports, 11
  • [44] Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
    Gide, Tuba N.
    Quek, Camelia
    Menzies, Alexander M.
    Tasker, Annie T.
    Shang, Ping
    Holst, Jeff
    Madore, Jason
    Lim, Su Yin
    Velickovic, Rebecca
    Wongchenko, Matthew
    Yan, Yibing
    Lo, Serigne
    Carlino, Matteo S.
    Guminski, Alexander
    Saw, Robyn P. M.
    Pang, Angel
    McGuire, Helen M.
    Palendira, Umaimainthan
    Thompson, John F.
    Rizos, Helen
    da Silva, Ines Pires
    Batten, Marcel
    Scolyer, Richard A.
    Long, Georgina V.
    Wilmott, James S.
    CANCER CELL, 2019, 35 (02) : 238 - +
  • [45] Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
    Pollack, M. H.
    Betof, A.
    Dearden, H.
    Rapazzo, K.
    Valentine, I.
    Brohl, A. S.
    Ancell, K. K.
    Long, G. V.
    Menzies, A. M.
    Eroglu, Z.
    Johnson, D. B.
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 250 - 255
  • [46] Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure
    Klee, Gina
    Kurzhals, Jonas
    Hagelstein, Victoria
    Zillikens, Detlef
    Recke, Andreas
    Langan, Ewan A.
    Terheyden, Patrick
    MELANOMA RESEARCH, 2021, 31 (05) : 464 - 471
  • [47] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma reply
    da Silva, Ines Pires
    Ahmed, Tasnia
    Reijers, Irene L. M.
    Warner, Allison Betof
    Patrinely, James Randall
    Serra-Bellver, Patricio
    Allayous, Clara
    Mangana, Joanna
    Zimmer, Lisa
    Trojaniello, Claudia
    Klein, Oliver
    Gerard, Camille L.
    Michielin, Olivier
    Haydon, Andrew
    Ascierto, Paolo A.
    Carlino, Matteo S.
    Lebbe, Celeste
    Lorigan, Paul
    Johnson, Douglas B.
    Sandhu, Shahneen
    Lo, Serigne N.
    Menzies, Alexander M.
    Long, Georgina, V
    LANCET ONCOLOGY, 2021, 22 (08): : E343 - E344
  • [48] First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)
    Nakamura, Y.
    Namikawa, K.
    Yoshikawa, S.
    Kiniwa, Y.
    Maekawa, T.
    Yamasaki, O.
    Isei, T.
    Matsushita, S.
    Nomura, M.
    Nakai, Y.
    Fukushima, S.
    Saito, S.
    Takenouchi, T.
    Tanaka, R.
    Kato, H.
    Otsuka, A.
    Matsuya, T.
    Baba, N.
    Nagase, K.
    Inozume, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S876 - S876
  • [49] Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
    Hao, Chunyan
    Tian, Jinhui
    Liu, Huiling
    Li, Fei
    Niu, Hongxia
    Zhu, Bingdong
    MEDICINE, 2017, 96 (26)
  • [50] Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
    Das, Rituparna
    Verma, Rakesh
    Sznol, Mario
    Boddupalli, Chandra Sekhar
    Gettinger, Scott N.
    Kluger, Harriet
    Callahan, Margaret
    Wolchok, Jedd D.
    Halaban, Ruth
    Dhodapkar, Madhav V.
    Dhodapkar, Kavita M.
    JOURNAL OF IMMUNOLOGY, 2015, 194 (03): : 950 - 959
12345